한글목차

세계의 마이코플라즈마 검출 시스템 시장은 제약회사, 생명공학 기업, 학술 및 연구기관, 위탁 연구기관, 진단 실험실 시장에서의 기회를 배경으로 미래가 유망할 것으로 예측됩니다. 세계 마이코플라즈마 검출 시스템 시장은 2025-2031년 연평균 복합 성장률(CAGR) 6.5%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 세포배양 오염 검사에 대한 수요 증가, 바이오의약품 연구 활동에 대한 투자 확대, 첨단 진단 기술 채택 확대 등입니다.

• Lucintel의 예측에 따르면 기술 유형별 카테고리에서는 중합효소 연쇄반응(PCR) 기반 시스템이 예측 기간 중 가장 높은 성장률을 보일 것으로 예측됩니다.
• 최종 용도별 카테고리에서는 CRO(위탁연구기관)가 가장 높은 성장률을 보일 것으로 예측됩니다.
• 지역별로는 아시아태평양(APAC)이 예측 기간 중 가장 높은 성장률을 보일 것으로 예측됩니다.

마이코플라즈마 검출 시스템 시장의 새로운 동향

마이코플라즈마 검출 시스템 시장은 기술 혁신의 시너지 효과, 바이오의약품의 품질관리에 대한 관심 증가, 신속하고 신뢰할 수 있는 결과에 대한 긴급한 요구에 힘입어 역동적인 변화를 경험하고 있습니다. 이러한 새로운 동향은 시장 환경을 크게 재구성하고 다양한 산업 분야에서 보다 효율적이고 통합적이며 접근하기 쉬운 검사 솔루션으로의 전환을 촉진하고 있습니다.

• 신속한 실시간 검출: 이러한 추세는 실시간 PCR과 같은 기법을 사용하여 종종 몇 시간 내에 빠른 결과를 제공하는 키트 및 시스템 개발에 중점을 두고 있습니다. 이는 기존 배양 기반 방식에 비해 처리 시간을 크게 단축하고, 광범위한 오염을 방지하며, 중요한 바이오프로세싱 및 연구 환경에서 신속한 의사결정을 가능하게 합니다.
• 자동화 및 고처리량 시스템: 자동화를 통해 수작업과 인적 오류를 최소화하고 대규모 검사 처리량을 향상시킵니다. 통합형 로봇 시스템 및 자동 핵산 추출 플랫폼이 보급되고 있으며, 제약 및 생명공학 기업이 대량의 시료를 효율적이고 일관성 있게 스크리닝할 수 있도록 지원하고 있습니다.
• Point of Care 검사: 특히 임상 진단을 위해 휴대가 간편하고 사용하기 쉬운 POC 마이코플라즈마 검출 장치의 개발이 진행되고 있습니다. 이러한 시스템은 센트럴 랩 밖에서도 신속한 결과를 제공하여 마이코플라즈마에 의한 호흡기 감염증의 조기 진단 및 치료 시작을 촉진함으로써 환자의 예후 개선에 기여합니다.
• 다중 검출 기능: 단일 분석으로 여러 마이코플라즈마 종, 심지어 다른 일반적인 오염물질을 동시에 검출할 수 있는 시스템이 주목받고 있습니다. 다중 검출은 효율성과 포괄성을 높이고, 보다 광범위한 오염 프로파일을 제공하며, 품질관리 실험실의 자원 활용을 최적화합니다.
• 디지털 통합 및 데이터 관리: 검출 시스템과 실험실 정보 관리 시스템(LIMS), 클라우드 기반 데이터 플랫폼과의 통합이 새로운 동향입니다. 이를 통해 원활한 데이터 전송, 자동 기록 관리, 추세 분석, 추적성 향상, 규제 준수 및 바이오 제조의 강력한 품질 보증에 필수적인 데이터 전송, 자동 기록 관리, 추세 분석 및 추적성을 실현합니다.

이러한 추세는 보다 빠르고 효율적이며 사용자 친화적인 솔루션으로의 혁신을 촉진함으로써 마이코플라즈마 검출 시스템 시장을 크게 변화시키고 있습니다. 기존의 실험실 환경을 넘어 마이코플라즈마 검출의 적용 범위를 확장하고, 중요 산업의 품질관리를 강화하며, 궁극적으로 보다 안전한 생물제제 및 환자 치료 개선에 기여하고 있습니다.

마이코플라즈마 검출 시스템 시장의 최근 동향

마이코플라즈마 검출 시스템 시장은 제약 및 생명공학 산업에서 강력한 품질관리의 중요성 때문에 빠르게 발전하고 있습니다. 이러한 발전은 세포배양 및 생물제제의 오염 방지에 필수적인 검출 속도, 정확도 및 접근성 향상에 초점을 맞추었습니다.

• PCR 기반 검사법의 발전: PCR(중합효소연쇄반응) 및 실시간 PCR 검사법의 대폭적인 개선으로 민감도와 특이도가 향상되었습니다. 이러한 발전으로 극히 낮은 농도의 마이코플라즈마 DNA를 검출할 수 있으며, 기존 배양법에 비해 신속하고 신뢰할 수 있는 결과를 제공합니다. 이는 바이오의약품 제조에 있으며, 매우 중요합니다.
• 신속한 측면 흐름 검사의 등장: 마이코플라즈마 검출을 위한 신속한 측면 흐름 검사의 도입으로 몇 분 안에 정성적인 결과를 얻을 수 있으며, 초기 선별 검사 및 현장 검사에 적합합니다. 이 기술은 신속성이 최우선인 일상적인 검사에서 편리하고 비용 효율적인 옵션을 제공합니다.
• 자동화 검출 시스템 개발: 자동 핵산 추출 및 분석 설정을 포함한 마이코플라즈마 검출의 자동화가 확산되고 있습니다. 이러한 시스템은 수작업을 줄이고, 인적 오류를 최소화하며, 샘플 처리 능력을 향상시켜 CRO(위탁연구기관)와 같은 대량 검사 환경에서 효율성과 일관성을 높입니다.
• 다균종 검출 키트에 집중: 각 제조업체들은 여러 가지 일반적인 마이코플라즈마 종을 동시에 검출할 수 있는 키트를 개발하고 있습니다. 이 다중 검출 기능은 검사 프로세스를 효율화하여 단일 분석으로 종합적인 오염 스크리닝을 가능하게 하고, 다양한 R&D 및 생산 환경에서 시간과 자원을 절약할 수 있도록 합니다.
• 첨단 세포배양 기술과의 통합: 마이코플라즈마 검출 시스템은 바이오리액터 모니터링을 포함한 첨단 세포배양 워크플로우에 통합되고 있습니다. 이러한 예방적 접근 방식은 실시간 오염 모니터링을 통해 바이오 제조 시설의 조기 개입과 대규모 제품 손실을 방지할 수 있습니다.

이러한 발전은 보다 신속하고 정확하며 효율적인 솔루션을 제공함으로써 마이코플라즈마 검출 시스템 시장에 큰 영향을 미치고 있습니다. 세포배양 및 바이오의약품 제품의 무결성을 높이고, 연구 결과에 대한 신뢰성을 향상시키며, 생명과학 산업 전반의 품질관리 프로세스를 효율화하고 있습니다.

목차

제1장 개요

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 마이코플라스마 검출 시스템 시장 : 기술 유형별

• 개요
• 기술 유형별 : 매력 분석
• 중합효소 연쇄 반응(PCR) 기반 시스템 : 동향과 예측(2019-2031년)
• 문화 기반 시스템 : 동향과 예측(2019-2031년)
• 면역학적 방법 : 동향과 예측(2019-2031년)
• 시퀀싱 방법 : 동향과 예측(2019-2031년)
• 질량분석 : 동향과 예측(2019-2031년)

제5장 마이코플라스마 검출 시스템 시장 : 제품 유형별

• 개요
• 제품 유형별 : 매력 분석
• 시약·키트 : 동향과 예측(2019-2031년)
• 기기·장비 : 동향과 예측(2019-2031년)
• 소프트웨어 솔루션 : 동향과 예측(2019-2031년)
• 서비스 : 동향과 예측(2019-2031년)
• 소모품 : 동향과 예측(2019-2031년)

제6장 마이코플라스마 검출 시스템 시장 : 용도별

• 개요
• 용도별 : 매력 분석
• 바이오의약품 제조 : 동향과 예측(2019-2031년)
• 미생물학적 검사 : 동향과 예측(2019-2031년)
• 세포배양 오염 검사 : 동향과 예측(2019-2031년)
• 진단과 임상 응용 : 동향과 예측(2019-2031년)
• 조사기관 : 동향과 예측(2019-2031년)

제7장 세계의 마이코플라스마 검출 시스템 시장 : 최종 용도별

• 개요
• 최종 용도별 : 매력 분석
• 제약회사 : 동향과 예측(2019-2031년)
• 바이오테크놀러지 기업 : 동향과 예측(2019-2031년)
• 학술연구기관 : 동향과 예측(2019-2031년)
• 계약 연구기관 : 동향과 예측(2019-2031년)
• 진단 실험실 : 동향과 예측(2019-2031년)
• 기타 : 동향과 예측(2019-2031년)

제8장 지역 분석

• 개요
• 지역별 마이코플라스마 검출 시스템 시장

제9장 북미의 마이코플라스마 검출 시스템 시장

• 개요
• 북미의 마이코플라스마 검출 시스템 시장(기술 유형별)
• 북미의 마이코플라스마 검출 시스템 시장(최종 용도별)
• 미국의 마이코플라스마 검출 시스템 시장
• 멕시코의 마이코플라스마 검출 시스템 시장
• 캐나다의 마이코플라스마 검출 시스템 시장

제10장 유럽의 마이코플라스마 검출 시스템 시장

• 개요
• 유럽의 마이코플라스마 검출 시스템 시장(기술 유형별)
• 유럽의 마이코플라스마 검출 시스템 시장(최종 용도별)
• 독일의 마이코플라스마 검출 시스템 시장
• 프랑스의 마이코플라스마 검출 시스템 시장
• 스페인의 마이코플라스마 검출 시스템 시장
• 이탈리아의 마이코플라스마 검출 시스템 시장
• 영국의 마이코플라스마 검출 시스템 시장

제11장 아시아태평양의 마이코플라스마 검출 시스템 시장

• 개요
• 아시아태평양의 마이코플라스마 검출 시스템 시장(기술 유형별)
• 아시아태평양의 마이코플라스마 검출 시스템 시장(최종 용도별)
• 일본의 마이코플라스마 검출 시스템 시장
• 인도의 마이코플라스마 검출 시스템 시장
• 중국의 마이코플라스마 검출 시스템 시장
• 한국의 마이코플라스마 검출 시스템 시장
• 인도네시아의 마이코플라스마 검출 시스템 시장

제12장 기타 지역의 마이코플라스마 검출 시스템 시장

• 개요
• 기타 지역의 마이코플라스마 검출 시스템 시장(기술 유형별)
• 기타 지역의 마이코플라스마 검출 시스템 시장(최종 용도별)
• 중동의 마이코플라스마 검출 시스템 시장
• 남미의 마이코플라스마 검출 시스템 시장
• 아프리카의 마이코플라스마 검출 시스템 시장

제13장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간 경쟁 관계
  • 바이어의 교섭력
  • 공급 기업의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제14장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 테크놀러지별 성장 기회
  • 제품 유형별 성장 기회
  • 용도별 성장 기회
  • 최종 용도별 성장 기회
• 세계의 마이코플라스마 검출 시스템 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증과 라이선싱
  • 합병, 인수, 계약, 제휴, 합병사업

제15장 밸류체인에서 주요 기업의 기업 개요

• Competitive Analysis
• Lonza
• Sartorius
• Eurofins
• Merck
• BioMerieux
• InvivoGen
• Charles River Laboratories
• Transgen Biotech
• Thermo Fisher Scientific
• Agilent Technologies

제16장 부록

• 도표
• 표 리스트
• 조사 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel 소개
• 문의

영문목차

The future of the global mycoplasma detection system market looks promising with opportunities in the pharmaceutical company, biotechnology firm, academic & research institution, contract research organization, and diagnostic laboratory markets. The global mycoplasma detection system market is expected to grow with a CAGR of 6.5% from 2025 to 2031. The major drivers for this market are the increasing demand for cell culture contamination testing, the rising investment in biopharmaceutical research activities, and the growing adoption of advanced diagnostic technologies.

• Lucintel forecasts that, within the technology type category, polymerase chain reaction based system is expected to witness the highest growth over the forecast period.
• Within the end use category, contract research organization is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Mycoplasma Detection System Market

The mycoplasma detection system market is experiencing a dynamic transformation, driven by a confluence of technological breakthroughs, an increased focus on quality control in biopharmaceuticals, and the urgent need for rapid, reliable results. These emerging trends are significantly reshaping the landscape, pushing towards more efficient, integrated, and accessible testing solutions across various industries.

• Rapid and Real-time Detection: This trend emphasizes the development of kits and systems that provide quick results, often within hours, using methods like real-time PCR. This significantly reduces turnaround time compared to traditional culture-based methods, enabling faster decision-making in critical bioprocessing and research environments to prevent widespread contamination.
• Automation and High-Throughput Systems: Automation minimizes manual labor and human error, increasing throughput for large-scale testing. Integrated robotic systems and automated nucleic acid extraction platforms are becoming prevalent, allowing pharmaceutical and biotechnology companies to screen a high volume of samples efficiently and consistently.
• Point-of-Care Testing: The development of portable and user-friendly POC mycoplasma detection devices is gaining traction, especially for clinical diagnostics. These systems offer rapid results outside centralized laboratories, facilitating quicker diagnosis and treatment initiation for respiratory infections caused by mycoplasma, improving patient outcomes.
• Multiplex Detection Capabilities: This trend involves systems that can detect multiple mycoplasma species or even other common contaminants simultaneously in a single assay. Multiplexing enhances efficiency and comprehensiveness, providing a broader contamination profile and optimizing resource utilization in quality control laboratories.
• Digital Integration and Data Management: Integration of detection systems with laboratory information management systems (LIMS) and cloud-based data platforms is an emerging trend. This allows for seamless data transfer, automated record-keeping, trend analysis, and improved traceability, crucial for regulatory compliance and robust quality assurance in biomanufacturing.

These trends are profoundly reshaping the mycoplasma detection system market by driving innovation towards faster, more efficient, and user-friendly solutions. They are expanding the applications of mycoplasma detection beyond traditional lab settings, enhancing quality control in critical industries, and ultimately contributing to safer biological products and improved patient care.

Recent Developments in the Mycoplasma Detection System Market

The mycoplasma detection system market is experiencing rapid advancements, driven by the critical need for robust quality control in the pharmaceutical and biotechnology industries. These developments focus on improving detection speed, accuracy, and accessibility, crucial for preventing contamination in cell cultures and biological products.

• Advancements in PCR-based Assays: Significant improvements in PCR (Polymerase Chain Reaction) and real-time PCR assays have led to higher sensitivity and specificity. These advancements enable the detection of extremely low levels of mycoplasma DNA, providing quicker and more reliable results compared to traditional culture methods, crucial for biopharmaceutical production.
• Emergence of Rapid Lateral Flow Tests: The introduction of rapid lateral flow tests for mycoplasma detection offers quick, qualitative results within minutes, making them suitable for initial screening and point-of-care applications. This development provides a convenient and cost-effective alternative for routine testing where speed is paramount.
• Development of Automated Detection Systems: Automation in mycoplasma detection, including automated nucleic acid extraction and assay setup, is gaining traction. These systems reduce manual labor, minimize human error, and increase sample throughput, enhancing efficiency and consistency in high-volume testing environments like contract research organizations.
• Focus on Multi-species Detection Kits: Manufacturers are developing kits capable of simultaneously detecting multiple common mycoplasma species. This multiplexing capability streamlines the testing process, providing comprehensive contamination screening with a single assay, thus saving time and resources in diverse research and production settings.
• Integration with Advanced Cell Culture Technologies: Mycoplasma detection systems are increasingly being integrated into advanced cell culture workflows, including bioreactor monitoring. This proactive approach allows for real-time contamination surveillance, enabling early intervention and preventing large-scale product losses in biomanufacturing facilities.

These developments are profoundly impacting the mycoplasma detection system market by offering faster, more accurate, and more efficient solutions. They are enhancing the integrity of cell cultures and biopharmaceutical products, fostering greater confidence in research outcomes, and streamlining quality control processes across the life sciences industry.

Strategic Growth Opportunities in the Mycoplasma Detection System Market

The mycoplasma detection system market presents substantial strategic growth opportunities across key applications, fueled by escalating demands for product safety and quality in the life sciences. These opportunities underscore the critical role of accurate and efficient mycoplasma detection in diverse sectors, driving innovation and market expansion.

• Biopharmaceutical Manufacturing Quality Control: The stringent regulatory requirements for biologics and cell-based therapies mandate rigorous mycoplasma testing throughout the manufacturing process. Offering comprehensive, automated, and rapid detection solutions for raw materials, in-process samples, and final products presents a major growth opportunity, ensuring product safety and compliance.
• Cell Therapy and Regenerative Medicine: The rapid expansion of cell therapy and regenerative medicine necessitates robust mycoplasma detection to ensure the safety of cell-based products used in human trials and treatments. Developing specialized, highly sensitive, and fast detection methods for these unique and critical applications is a significant growth area.
• Academic and Research Laboratories: Academic and research institutions extensively use cell cultures, making them highly susceptible to mycoplasma contamination. Providing user-friendly, cost-effective, and reliable mycoplasma detection kits and services for routine screening offers a substantial growth opportunity, maintaining the integrity of research findings.
• Contract Research Organizations and Contract Manufacturing Organizations (CMOs): The increasing outsourcing of R&D and manufacturing activities to CROs and CMOs drives demand for efficient mycoplasma detection services. Partnering with or providing tailored solutions to these organizations, which manage diverse cell lines and production batches, represents a strategic growth avenue.
• Clinical Diagnostics and Infection Control: While historically focused on cell culture, the re-emergence of Mycoplasma pneumoniae infections highlights a growing opportunity in clinical diagnostics. Developing rapid, accurate, and point-of-care mycoplasma detection systems for respiratory infections could tap into a significant clinical market and enhance public health surveillance.

These strategic growth opportunities are profoundly impacting the mycoplasma detection system market by diversifying its application base, driving innovation in sensitivity and speed, and fostering partnerships across critical healthcare and research sectors. They underscore the indispensable role of mycoplasma detection in ensuring the safety and efficacy of biological products and medical treatments.

Mycoplasma Detection System Market Driver and Challenges

The mycoplasma detection system market navigates a complex interplay of drivers and challenges, where technological advancements, growing biopharmaceutical production, and regulatory mandates propel its expansion, while high costs, technical complexities, and the need for skilled personnel pose significant hurdles. This dynamic influences market growth and accessibility.

The factors responsible for driving the mycoplasma detection system market include:

1. Increasing Cell Culture Contamination Concerns: The rising incidence of mycoplasma contamination in cell cultures used across research and biopharmaceutical production is a primary driver. Contamination can lead to unreliable experimental results and compromised product quality, creating an urgent demand for effective detection.

2. Growth in Biopharmaceutical and Biotech Industries: The booming biopharmaceutical and biotechnology sectors, driven by drug discovery, vaccine development, and cell therapies, rely heavily on cell culture. This expansion directly translates into increased demand for mycoplasma detection systems to ensure product purity and patient safety.

3. Stringent Regulatory Guidelines: Regulatory bodies worldwide, such as the FDA and EMA, impose strict guidelines for mycoplasma testing in biological products. Adherence to these regulations is mandatory for product approval and market entry, compelling manufacturers to implement robust detection strategies.

4. Technological Advancements in Detection Methods: Continuous innovation in detection technologies, particularly in PCR-based assays and real-time detection, offers faster, more sensitive, and specific results. These technological leaps are making detection more efficient and reliable, driving their adoption across industries.

5. Increasing Research and Development Activities: Higher investments in R&D across life sciences, especially in areas like gene editing and personalized medicine, necessitate reliable cell cultures. This drives the demand for consistent and accurate mycoplasma testing to ensure the integrity of experimental data and novel therapeutic development.

Challenges in the mycoplasma detection system market are:

1. High Cost of Advanced Detection Systems: The significant initial investment required for advanced mycoplasma detection systems, especially automated and high-throughput platforms, can be a major barrier. This cost can deter smaller laboratories or those with limited budgets from adopting cutting-edge technologies.

2. Technical Complexity and Skill Requirements: Performing highly sensitive mycoplasma detection assays, particularly molecular-based methods, often requires specialized technical expertise and skilled personnel. The shortage of such trained professionals can limit the widespread adoption and efficient operation of these advanced systems.

3. Variability in Mycoplasma Species and Detection Limits: Mycoplasma comprises diverse species, and detection systems might not be equally effective against all of them, or some may have varying detection limits. This variability can lead to false negatives or the need for multiple tests, complicating comprehensive contamination control.

The mycoplasma detection system market is experiencing robust growth, primarily fueled by the burgeoning biopharmaceutical industry and stringent quality control demands. However, addressing challenges related to high costs and the need for specialized expertise will be paramount to ensuring widespread adoption and fully realizing the market's potential in safeguarding critical biological processes.

List of Mycoplasma Detection System Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mycoplasma detection system companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mycoplasma detection system companies profiled in this report include-

• Lonza
• Sartorius
• Eurofins
• Merck
• BioMerieux
• InvivoGen
• Charles River Laboratories
• Transgen Biotech
• Thermo Fisher Scientific
• Agilent Technologies

Mycoplasma Detection System Market by Segment

The study includes a forecast for the global mycoplasma detection system market by technology type, product type, application, end use, and region.

Mycoplasma Detection System Market by Technology Type [Value from 2019 to 2031]:

• Polymerase Chain Reaction Based Systems
• Culture-based Systems
• Immunological Methods
• Sequencing Methods
• Mass Spectrometry

Mycoplasma Detection System Market by Product Type [Value from 2019 to 2031]:

• Reagents & Kits
• Instrument & Equipment
• Software Solutions
• Services
• Consumables

Mycoplasma Detection System Market by Application [Value from 2019 to 2031]:

• Biopharmaceutical Manufacturing
• Microbiological Testing
• Cell Culture Contamination Testing
• Diagnostics & Clinical Applications
• Research Laboratories

Mycoplasma Detection System Market by End Use [Value from 2019 to 2031]:

• Pharmaceutical Companies
• Biotechnology Firms
• Academic & Research Institutions
• Contract Research Organizations
• Diagnostic Laboratories
• Others

Country Wise Outlook for the Mycoplasma Detection System Market

The mycoplasma detection system market is rapidly advancing, driven by increasing concerns over cell culture contamination in the biopharmaceutical and research sectors. Innovations in rapid, highly sensitive, and automated detection methods are crucial for ensuring product safety and maintaining stringent quality control standards across various applications globally.

• United States: The US market leads in adopting advanced PCR-based and nucleic acid amplification tests (NAATs) for rapid and highly sensitive mycoplasma detection. Stringent regulatory guidelines from the FDA and significant R&D investments in biopharmaceuticals are driving the demand for precise and efficient testing solutions.
• China: China's market is experiencing a significant surge in demand, fueled by a rising number of Mycoplasma pneumoniae infections in clinical settings and expanding biopharmaceutical manufacturing. Local companies are investing in rapid diagnostic kits and advanced molecular detection methods to meet this growing need and enhance public health.
• Germany: Germany shows strong market growth, driven by its robust biotechnology and pharmaceutical industries. There's a focus on high-quality, reliable mycoplasma detection systems, with established players like Merck KGaA contributing to advanced R&D and the adoption of automated testing platforms in research and production.
• India: India's mycoplasma detection market is expanding due to increasing investments in biotechnology and pharmaceutical R&D, alongside a growing awareness of contamination risks. The market is witnessing a rise in demand for cost-effective and rapid detection kits, catering to emerging research institutes and bioproduction facilities.
• Japan: Japan's market is characterized by a high emphasis on precision and automation in mycoplasma detection. With a strong biopharmaceutical sector, there's a continuous demand for cutting-edge PCR and real-time detection systems to ensure the safety and quality of cell cultures and biological products.

Features of the Global Mycoplasma Detection System Market

• Market Size Estimates: Mycoplasma detection system market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Mycoplasma detection system market size by various segments, such as by technology type, product type, application, end use, and region in terms of value ($B).
• Regional Analysis: Mycoplasma detection system market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different technology type, product type, application, end use, and regions for the mycoplasma detection system market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mycoplasma detection system market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the mycoplasma detection system market by technology type (polymerase chain reaction based systems, culture-based systems, immunological methods, sequencing methods, and mass spectrometry), product type (reagents & kits, instrument & equipment, software solutions, services, and consumables), application (biopharmaceutical manufacturing, microbiological testing, cell culture contamination testing, diagnostics & clinical applications, and research laboratories), end use (pharmaceutical companies, biotechnology firms, academic & research institutions, contract research organizations, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Mycoplasma Detection System Market by Technology Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Technology Type
• 4.3 Polymerase Chain Reaction based systems: Trends and Forecast (2019-2031)
• 4.4 Culture-based systems: Trends and Forecast (2019-2031)
• 4.5 Immunological Methods: Trends and Forecast (2019-2031)
• 4.6 Sequencing Methods: Trends and Forecast (2019-2031)
• 4.7 Mass Spectrometry: Trends and Forecast (2019-2031)

5. Global Mycoplasma Detection System Market by Product Type

• 5.1 Overview
• 5.2 Attractiveness Analysis by Product Type
• 5.3 Reagents & Kits: Trends and Forecast (2019-2031)
• 5.4 Instrument & Equipment: Trends and Forecast (2019-2031)
• 5.5 Software Solutions: Trends and Forecast (2019-2031)
• 5.6 Services: Trends and Forecast (2019-2031)
• 5.7 Consumables: Trends and Forecast (2019-2031)

6. Global Mycoplasma Detection System Market by Application

• 6.1 Overview
• 6.2 Attractiveness Analysis by Application
• 6.3 Biopharmaceutical Manufacturing: Trends and Forecast (2019-2031)
• 6.4 Microbiological Testing: Trends and Forecast (2019-2031)
• 6.5 Cell Culture Contamination Testing: Trends and Forecast (2019-2031)
• 6.6 Diagnostics & Clinical Applications: Trends and Forecast (2019-2031)
• 6.7 Research Laboratories: Trends and Forecast (2019-2031)

7. Global Mycoplasma Detection System Market by End Use

• 7.1 Overview
• 7.2 Attractiveness Analysis by End Use
• 7.3 Pharmaceutical Companies: Trends and Forecast (2019-2031)
• 7.4 Biotechnology Firms: Trends and Forecast (2019-2031)
• 7.5 Academic & Research Institutions: Trends and Forecast (2019-2031)
• 7.6 Contract Research Organizations: Trends and Forecast (2019-2031)
• 7.7 Diagnostic Laboratories: Trends and Forecast (2019-2031)
• 7.8 Others: Trends and Forecast (2019-2031)

8. Regional Analysis

• 8.1 Overview
• 8.2 Global Mycoplasma Detection System Market by Region

9. North American Mycoplasma Detection System Market

• 9.1 Overview
• 9.2 North American Mycoplasma Detection System Market by Technology Type
• 9.3 North American Mycoplasma Detection System Market by End Use
• 9.4 United States Mycoplasma Detection System Market
• 9.5 Mexican Mycoplasma Detection System Market
• 9.6 Canadian Mycoplasma Detection System Market

10. European Mycoplasma Detection System Market

• 10.1 Overview
• 10.2 European Mycoplasma Detection System Market by Technology Type
• 10.3 European Mycoplasma Detection System Market by End Use
• 10.4 German Mycoplasma Detection System Market
• 10.5 French Mycoplasma Detection System Market
• 10.6 Spanish Mycoplasma Detection System Market
• 10.7 Italian Mycoplasma Detection System Market
• 10.8 United Kingdom Mycoplasma Detection System Market

11. APAC Mycoplasma Detection System Market

• 11.1 Overview
• 11.2 APAC Mycoplasma Detection System Market by Technology Type
• 11.3 APAC Mycoplasma Detection System Market by End Use
• 11.4 Japanese Mycoplasma Detection System Market
• 11.5 Indian Mycoplasma Detection System Market
• 11.6 Chinese Mycoplasma Detection System Market
• 11.7 South Korean Mycoplasma Detection System Market
• 11.8 Indonesian Mycoplasma Detection System Market

12. ROW Mycoplasma Detection System Market

• 12.1 Overview
• 12.2 ROW Mycoplasma Detection System Market by Technology Type
• 12.3 ROW Mycoplasma Detection System Market by End Use
• 12.4 Middle Eastern Mycoplasma Detection System Market
• 12.5 South American Mycoplasma Detection System Market
• 12.6 African Mycoplasma Detection System Market

13. Competitor Analysis

• 13.1 Product Portfolio Analysis
• 13.2 Operational Integration
• 13.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

• 14.1 Value Chain Analysis
• 14.2 Growth Opportunity Analysis
  • 14.2.1 Growth Opportunities by Technology Type
  • 14.2.2 Growth Opportunities by Product Type
  • 14.2.3 Growth Opportunities by Application
  • 14.2.4 Growth Opportunities by End Use
• 14.3 Emerging Trends in the Global Mycoplasma Detection System Market
• 14.4 Strategic Analysis
  • 14.4.1 New Product Development
  • 14.4.2 Certification and Licensing
  • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

• 15.1 Competitive Analysis
• 15.2 Lonza
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.3 Sartorius
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.4 Eurofins
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.5 Merck
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.6 BioMerieux
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.7 InvivoGen
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.8 Charles River Laboratories
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.9 Transgen Biotech
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.10 Thermo Fisher Scientific
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.11 Agilent Technologies
  • Company Overview
  • Mycoplasma Detection System Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

16. Appendix

• 16.1 List of Figures
• 16.2 List of Tables
• 16.3 Research Methodology
• 16.4 Disclaimer
• 16.5 Copyright
• 16.6 Abbreviations and Technical Units
• 16.7 About Us
• 16.8 Contact Us